TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Nykode Therapeutics ASA
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
733
|
1,148
|
681 |
| Financial expenses |
522
|
416
|
614 |
| Earnings before taxes |
-3,842
|
-3,922
|
-4,843 |
| Total assets |
12,956
|
18,521
|
21,040 |
| Current assets |
9,882
|
14,739
|
20,128 |
| Current liabilities |
768
|
1,833
|
3,704 |
| Equity capital |
11,499
|
15,236
|
14,917 |
| - share capital |
31
|
33
|
32 |
| Employees (average) | 139 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
88.8%
|
82.3%
|
70.9% |
| Turnover per employee | 5 | ||
| Profit as a percentage of turnover |
-524.1%
|
-341.6%
|
-711.2% |
| Return on assets (ROA) |
-25.6%
|
-18.9%
|
-20.1% |
| Current ratio |
1286.7%
|
804.1%
|
543.4% |
| Return on equity (ROE) |
-33.4%
|
-25.7%
|
-32.5% |
| Change turnover |
-356
|
510
|
-2,546 |
| Change turnover % |
-33%
|
80%
|
-79% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.